Home MarketStrides Shasun Ltd.

Strides Shasun Ltd. Stock Info: As on 2018-01-19 14:59:59

Nse

802.70

0.70(0.09%)
Change%
52 Week Range
752.30
9.00
1,274.70
3.00
Open805.80
Day's Range721.80 - 882.20
Value Traded (in ₹ Cr.) 8.79

Bse

803.95

4.60(0.58%)
Change %
52 Week Range
754.00
9.00
1,259.00
3.00
Open806.00
Day's Range719.42 - 879.29
Value Traded (in ₹ Cr.) 1.22

Stock Exchange

Category No. Of Shares Share %
ForeignPromoters 0.00 0.00%
IndianPromoters 27,848,384.00 31.12%
Mutual Funds/UTI 13,470,250.00 15.05%
FII 30,615,875.00 34.21%
Employee 0.00 0.00%
Public 11,325,984.00 12.66%
Government 0.00 0.00%
Others 5,466,703.00 6.11%
More

Key Statistics

Valuation Measures
Market Cap / Sales Ratio 4.41
Basic EPS (Rs.) 19.50
Cash EPS 29.87
BVPerShare Excl 350.93
Operating Revenue 246.62
PBDITPerShare 47.35
Dividend 4.00
NPPerShare 18.03
Current Ratio 2.06
Quick Ratio 1.77
PriceToBV 3.10
Earnings 0.01
PBDIT Margin 19.19
PBT Margin 8.59
NP Margin 7.30
Return On Assets 3.00
Retention Ratios 73.63
Parameter Mar-16 (₹ Cr.) Yoy%change
Total Income 2,344.45
Total Expenses 2,129.99
EBITDA 423.02
PBT 189.29
PAT 161.07
Net Income 161.07
More
Parameter Mar-16 (₹ Cr.) 6M % change
Total Income 1,244.33
Total Expenses 1,082.98
EBITDA 106.21
PBT 108.08
PAT 108.97
Net Income 0.00
More
Total Assets
Total Assets
Parameter Mar-16 (₹ Cr.) Yoy%change
Total share capital 89.35
Net worth 3,135.41
Investments 2,366.87
Total Liability 5,363.99
Total debt 1,425.11
Net block 1,238.92
Total Assets 5,363.99
Parameter Mar-16 (₹ Cr.) 6M % change
Total share capital 89.35
Net worth 3,135.40
Investments 2,366.87
Total Liability 5,363.99
Total debt 1,425.11
Net block 1,238.92
Total Assets 5,363.99
Company Curr Price Prev. Close Change% W's Low/High

Aarti Drugs Ltd.

699 715.95 -2.37
707.6774

Abbott India Ltd.

5470.95 5435.7 0.65
5335.655550

Ajanta Pharma Ltd.

1550 1533.2 1.1
1480.21562

Albert David Ltd.

400 412.55 -3.04
412.55498

Alembic Ltd.

63.35 59 7.37
57.462.5

Alembic Pharmaceuticals Ltd.

547 540.85 1.14
530575

Alkem Laboratories Ltd.

2240.8 2249.1 -0.37
22252319
Company Curr Price Prev. Close Change% W's Low/High

Aarey Drugs & Pharmaceuticals Ltd.

56.5 57.3 -1.4
5763.5

Aarti Drugs Ltd.

699.95 717.55 -2.45
715771.05

Aayush Food & Herbs Ltd.

61.95 59 5
56.5562.9

Abbott India Ltd.

5464.95 5432.4 0.6
5335.055549.95

ABL Bio-Technologies Ltd.

0.81 0.78 3.85
0.750.81

Addlife Pharma Ltd.

0.46 0 0
0.460.5

Adinath Bio-Labs Ltd.

0.3 0.31 -3.23
0.30.3
More
Parameter Mar-16(in ₹ Cr.)
Cash from operating activities 83.56
Cash from investing activities -1,064.38
Cash from financing activities 1,570.84
Net change in cash 591.96

Stock Held By Mutual Fund Schemes

Scheme Holding (%)
SBI Blue Chip Fund 1.07%
SBI Magnum Midcap Fund 2.63%
DSP BlackRock Balanced Fund 1.40%
HDFC Mid-Cap Opportunities Fund - Regular Plan 0.45%
SBI Pharma Fund 7.34%
DSP BlackRock Tax Saver Fund 1.74%

Alembic jumps 9% on share buyback plan

Shares of Alembic surged over 9 per cent on the Bombay Stock Exchange after the drug maker said that its board will meet on January 23, 2018 to consider share buyback proposal. Boosted by the development, stocks of the company gained as much 9.32 per cent to touch an intra-day high of Rs 64.50 apiece on the Bombay Stock Exchange. In a similar fashion, shares of the firm were trading 7.54 per cent higher at Rs 63.45 apiece on the National Stock Exchange. Meanwhile, the broader benchmark BSE Sensex was trading at 35,400.98, up 140.69 points, or 0.40 per cent, at 11:05 hours.

19-01-2018 10:54

Moody's assigns Baa2 to EXIM India's note drawdown

Moody's Investors Service, a global rating agency, has assigned a Baa2 rating to Export-Import Bank of India's (EXIM India) proposed senior unsecured notes, issued under its USD 10 billion Global Medium Term Note (GMTN) program. The drawdown is from its head office in India, and will be listed on the London Stock Exchange International Securities Market and the Singapore Exchange Securities Trading Limited. The rating outlook is stable, says Moody's in a report. The senior unsecured rating is subject to receipt of final documentation, the terms and conditions of which are not expected to change in any material way from the draft documents reviewed by Moody's. EXIM India's senior unsecured rating incorporates the bank's Baseline Credit Assessment (BCA) of ba3; and our assessment of a very high dependence on, and the very high (government-backed) probability of support from, the Government of India (Baa2 stable), said Moody’s. The BCA of ba3 incorporates EXIM India's strong capital buffers and a good liquidity profile with assets and liabilities well matched in terms of both maturity and currency. In addition, the BCA also accounts for the deterioration in the bank's asset quality, which we expect will increase credit costs and take a toll on overall profitability.

19-01-2018 10:11

RBI hikes FIIs limit in HealthCare Global to 100%

The Reserve Bank of India on Thursday notified that the foreign investment limit for investment by Foreign Portfolios Investors (FPIs) in Healthcare Global Enterprises Limited has increased from 24 per cent to 100 per cent of its paid up capital. HealthCare Global Enterprises Limited has passed necessary resolutions of its Board of Directors and General Body as required under the FEMA 1999 and the regulations framed thereunder. The increase is subject to regulation of Foreign Exchange Management Regulations, 2017 dated November 07, 2017, as amended from time to time, and the onus of compliance with the limits prescribed for the company is on the company. Further, owing to the above increase in the investment limit, it is notified that the aggregate shareholding by FPIs in HealthCare Global Enterprises Limited has gone below the prescribed FPIs investment limit for the company. Hence, the restrictions placed on the purchase of shares of the above company by FPIs, it added.

19-01-2018 10:07

Karnataka Bank bags award from FIEO

Karnataka Bank has said that it been awarded as the ’Best Financial Services & Foreign Exchange Earner in Southern Region’ for the year 2016-17 under GOLD Category by Federation of Indian Export Organizations (FIEO) Southern Region for the support extended to export business. Shri M Venkaiah Naidu, Hon’ble Vice President of India handed over the award during the Export Excellence Award function of FIEO held on 18.01.2018 at Chennai. Shri Raghavendra Bhat M, Chief General Manager, received the award on behalf of the Bank. Seen on the occasion are Shri. Banwarilal Purohit, Governor of Tamil Nadu, Dr. A. Sakthivel, Regional Chairman, Southern Region, FIEO, Shri Prasandan Thenisseri, AGM, Chennai – RO, Karnataka Bank and others. Meanwhile, shares of the bank were trading at Rs 158.55 apiece, up 0.35 per cent from the previous close at 09:27 hours on BSE.

19-01-2018 09:19

Axis Securities takes membership of MCX

Multi Commodity Exchange of India Ltd (MCX) has said that Axis Securities Ltd., a subsidiary of Axis Bank Ltd., has become the first bank sponsored broking entity to take membership of Multi Commodity Exchange of India Ltd (MCX) after the Reserve Bank of India (RBI) allowed banks to provide broking services in commodities derivatives. The participation of entities backed by financial institutions such as banks, in the commodity derivatives market will provide great impetus for the overall development of the commodities market in India whilst providing the banks and their broking arms new business opportunities, especially given their large customer base and vast network of branches across the country. The membership to Axis Securities Ltd., granted in first week of December 2017 has since then seen both MCX and Axis Securities engage in planning the education & training calendar to enable smooth roll out of services at Axis Securities Ltd. Meanwhile, shares of the company were trading at Rs 840.85 apiece, down 0.24 per cent from the previous close at 09:27 hours on BSE.

19-01-2018 09:18

Strides Shasun L - Investor Grievance Report For The Quarter Ended December 31, 2017

Investor Grievance Report for the quarter ended December 31, 2017 pursuant to Regulation 13 (3) of SEBI (Listing Obligations and Disclosure Requirement) Regulation, 2015

18-Jan-2018 06:20 PM

Strides Shasun L - Shareholding for the Period Ended December 31, 2017

Strides Shasun Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2017.

18-Jan-2018 05:49 PM

Strides Shasun L - Shareholders meeting

Strides Shasun Limited has informed the Exchange regarding Proceedings of Court Convened General Meeting held on December 27, 2017. Further, the company has submitted the Exchange a copy of Srutinizers report along with voting results.

28-Dec-2017 12:33 PM

Strides Shasun L - Equity Shareholders Of The Company Approve The Composite Scheme Of Arrangement

We are pleased to inform that the Tribunal Convened Meeting of Equity Shareholders of the Company was held on December 27, 2017 as directed by Mumbai Bench of Hon'ble National Company Law Tribunal ('NCLT') vide its Order dated November 17, 2017 in Company Scheme Application No. 876 of 2017 to approve Composite Scheme of Arrangement between Strides Shasun Limited, SeQuent Scientific Limited and Solara Active Pharma Sciences Limited and their respective Shareholders and Creditors ('Composite Scheme') pursuant to the provisions of Sections 230 - 232 of the Companies Act, 2013.

The Composite Scheme was approved by the equity shareholders of the Company with 99.99% votes for the resolution through e-voting, postal ballot and poll conducted at the meeting.

Pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 ('Listing Regulations'), enclosed are the following:

a)Summary of Proceedings of the Meeting as required under Regulation 30, Part A of Schedule III of the Listing Regulations as Annexure A;

b)Details of results of remote e-voting, postal ballot and poll conducted at the meeting as required under Regulation 44(3) of the Listing Regulations as Annexure B;

c) Scrutinizer's Report as Annexure C.

The approval is deemed to have been received on December 27, 2017.

The Company shall file a petition with the NCLT, Mumbai Bench for final sanction of the Composite Scheme.

Please also note that the Composite Scheme was approved by the equity shareholders of Solara Active Pharma Sciences Limited ('Solara') with requisite majority at the Tribunal Convened Meeting of the Equity Shareholders of Solara held on December 27, 2017 as directed by Mumbai Bench of Hon'ble National Company Law Tribunal vide its Order dated November 17, 2017 in Company Scheme Application No. 877 of 2017.

28-Dec-2017 12:29 PM

Strides Shasun to acquire controlling stake in Trinity Pharma

Strides Shasun said that it entered into agreement to acquire controlling stake in Trinity. Strides Pharma Asia Pte, Singapore, a wholly owned subsidiary of Strides Shasun has entered into definitive agreements with Trinity Pharma proprietary, South Africa for acquisition of controlling stake in Trinity. Strides Pharma Asia Pte will acquire 55 percent stake in Trinity for a cash consideration of South African Rand 55 million (Approximately Rs 27.5 crore) The transaction is subject to customary closing conditions including approvals from the South African regulatory authority, transaction regulation panel and expected to close on or before January 5, 2018. The share has declined 29 percent in last 9 months. Meanwhile, shares of the company were trading at Rs 817.00 apiece, up 2.73 per cent from the previous close at 12:00 hours on BSE.

20-Dec-2017 11:55 AM

Strides Shasun L - Investor Grievance Report For The Quarter Ended December 31, 2017

Investor Grievance Report for the quarter ended December 31, 2017 pursuant to Regulation 13 (3) of SEBI (Listing Obligations and Disclosure Requirement) Regulation, 2015

18-Jan-2018 06:20 PM

Strides Shasun L - Shareholding for the Period Ended December 31, 2017

Strides Shasun Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2017.

18-Jan-2018 05:49 PM

Strides Shasun L - Equity Shareholders Of The Company Approve The Composite Scheme Of Arrangement

We are pleased to inform that the Tribunal Convened Meeting of Equity Shareholders of the Company was held on December 27, 2017 as directed by Mumbai Bench of Hon'ble National Company Law Tribunal ('NCLT') vide its Order dated November 17, 2017 in Company Scheme Application No. 876 of 2017 to approve Composite Scheme of Arrangement between Strides Shasun Limited, SeQuent Scientific Limited and Solara Active Pharma Sciences Limited and their respective Shareholders and Creditors ('Composite Scheme') pursuant to the provisions of Sections 230 - 232 of the Companies Act, 2013.

The Composite Scheme was approved by the equity shareholders of the Company with 99.99% votes for the resolution through e-voting, postal ballot and poll conducted at the meeting.

Pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 ('Listing Regulations'), enclosed are the following:

a)Summary of Proceedings of the Meeting as required under Regulation 30, Part A of Schedule III of the Listing Regulations as Annexure A;

b)Details of results of remote e-voting, postal ballot and poll conducted at the meeting as required under Regulation 44(3) of the Listing Regulations as Annexure B;

c) Scrutinizer's Report as Annexure C.

The approval is deemed to have been received on December 27, 2017.

The Company shall file a petition with the NCLT, Mumbai Bench for final sanction of the Composite Scheme.

Please also note that the Composite Scheme was approved by the equity shareholders of Solara Active Pharma Sciences Limited ('Solara') with requisite majority at the Tribunal Convened Meeting of the Equity Shareholders of Solara held on December 27, 2017 as directed by Mumbai Bench of Hon'ble National Company Law Tribunal vide its Order dated November 17, 2017 in Company Scheme Application No. 877 of 2017.

28-Dec-2017 12:29 PM

Corporate Details

About Management

2002 -Board approves for the allotment of 210,955 shares of the company at Rs.10 each to the share holders of Bombay Drugs & Pharmas Ltd. -Zenith Pharmaceuticals Ltd acquires 71% shares through preferential issue route. -Board approves for the proposal of restructuring its Cram division by hiving off into two separate company under the provisions of the companies act. -Incorporates 'Strides Africa Ltd' at British Virgin Island with an authorised capital of US $ 200,000 as 100% wholly owned subsidiary. -Board decides to change the name of the company to 'Strides Arcolab (FA)' to reflect the change in the business focus and operations. 2003 -Nominates Mr Francis Pinto as the Director on the Board of the company. -Forges an exclusive co-operation alliance with the South Africa based drug manufacturer Aspen Pharmacare, mainly to share the product development expertise and quality systems. -Concludes the strategic development and manufacturing agreement with Sorm Co. Ltd for long term supply of Generics, OTC and Nutraceutical products. -Changes in the Management: Appoints Mr V Hariharan as CFO, Mr Joe Thomas as President, and Mr Krishna Kumar Menon as COO. -Board approves for the reorganization of subsidiaries of the company and for write off of dimunition in value of investments made in subsidiaries by the company. -Strides inks MoU with Ribbon SRL for Cephalosporin 2004 -Major Fire occurs in Private Custom Bonded warehouse in Mexico -Strides Arcolab Limited has entered into a memorandum of understanding with BITS, Pilani for an ``off campus collaborative programme''. As part of the partnership, Strides has launched a new initiative called STEP (Strides Training and Education Plan) intend to offer their employees an opportunity to acquire a MS in Pharma Operations & Management while on the job. 2005 - Enters into an agreement with Mayne Pharma Business Unit of Australia based Mayne Group Ltd, to develop and manufacture a range of six anti-infective products that Mayne will market and distribute in the US and European markets. -Strides Arcolab enters into an agreement for private placement issue - Strides Arcolab signs License Agreement with KV Pharma for exclusive marketing rights in the United States and Canada for 10 new generic drugs -Strides acquires sterile manufacturing facility in Poland 2007 - Strides Arcolab has got tentative permission from the United States Food and Drug Administration (USFDA) for Efavirenz tablets, an anti-HIV drug. Efavirenz, is the generic version of Bristol Myers Squibb's Sustiva, which helps in preventing the HIV virus from reproduction. - Strides Arcolab receives 2 more NDA approvals from US-FDA. 2008 - Strides Arcolab Ltd on March 19, 2008 announced its third ANDA approval for Fosphenytoin Injection 50mg/mL in 2 ml and 10 ml vials. 2010 - Strides Arcolab Ltd has informed that Mr. V. S. Iyer has been appointed as an Executive Director of the Company. 2011 -Strides Arcolab Receives US FDA NOD To Commercialize First Sterlite -Strides announces First European Approval for Oncology Product -Strides Arcolab receives US FDA Nod to Commercialize First Liquid -StridesArcoL Update on acquisition of outstanding minority shareholding in Ascent Pharmahealth Limited -Strides Arcolab joins the Malaysian Bio-xcell Ecosystem 2012 -Strides Arcolab Announces US FDA approval for its 'Brazilian Sterile -Strides Arcolab receives US FDA approval for Methotrexate Injection -Strides Arcolab Announces Health Canada Approval For Tobramycin Injection -Strides Arcolab acquires Sterile Formulations facility to expand core injectable biz -Strides collaborates with Gilead Sciences 2013 -Strides Arcolab receives ANDA approval from USFDA for Tenofovir Disoproxil Fumarate and Emtricitabine Tablet. - Strides Arcolab announces US FDA approval for its Italian Semi-solids and Oinment facility. - Strides announces WHO pre-qualification for Artemether + Lumifantrine . -StelisBiopharma and Pieris Forge Alliance for Novel Anticalin Therapeutics in Ophthalmology. -Strides Arcolab - Re-branding Biotech Business as ''Stelis''. -Strides Arcolab - Pfenex Inc. and Agila Biotech Private Ltd Announce Joint Venture to Develop Biosimilar Products for the Global Market. 2014 -- Medicines for Malaria Venture announces collaborations with Cipla and Strides. -Strides Arcolab makes strategic investment in Oncobiologics Inc., USA. - Strides partners with Gilead Sciences Inc, to bring Hepatitis C cure to 91 developing countries. -Strides Arcolab receives US FDA approval for Buspirone Tablets. -Strides Arcolab receives US FDA approval for Calcitriol Softgel. -Strides Arcolab acquires 'Raricap' and India Branded Generic Business of Bafna. -Strides Arcolab to acquire Shasun Pharma in all stock deal. 2015 -Strides Arcolab Ltd. has entered into an agreement with Fortuna Public Relations Pvt. Ltd., Delhi appointing them as Company's Public Relations Agenc -Strides Arcolab Ltd that it has entered into a licensing agreement with Gilead Sciences Inc, -Strides Arcolab Ltd has launched the generic drug Sofosbuvir in India "Virso" -Strides Arcolab gets USFDA nod for Polyethylene Glycol 3350 -Strides Arcolab gets USFDA nod for HIV treatment drug -Strides Arcolab Ltd has approved the merger of Shasun Pharmaceuticals Ltd with the company. -Strides Arcolab has completed the Rs 1,910-crore acquisition of Aspen Pharmacare, Australia. -Strides Arcolab acquires CNS divisions of erstwhile Ranbaxy -Strides Arcolab Ltd has changed from its present name "Strides Arcolab Limited" to "Strides Shasun Limited" 2016 -Strides Shasun updates on "Acquisition of seven brands from Johnson & Johnson". -Strides Shasun update on "Acquisition of CNS divisions of erstwhile Ranbaxy". -"Strides Shasun to acquire a strategic stake in Generic Partners Holdings, Australia". -"Strides Shasun to acquire controlling stake in Universal Corporation, Kenya". -"Strides Shasun receives USFDA Tentative Approval for Efavirenz Tablet". - "Strides Shasun announces successful completion of US FDA inspection at its Oral Dosage Facility in Bangalore".

Registered Office

CHENNAI OFFICE: `Batra Centre', 3rd and 4th Floor, 28, Sardar Patel Road, Guindy,

044-43446700,22207500,,      044-22350278,

Registrar Details

Karvy Computershare Private Ltd.